Uyl-de Groot CA - Search Results

1

Results from Expanded Access Programs: A Review of Academic Literature.

Polak TB, Cucchi DGJ, Schelhaas J, Ahmed SS, Khoshnaw N, van Rosmalen J, Uyl-de Groot CA. Polak TB, et al. Drugs. 2023 Jun;83(9):795-805. doi: 10.1007/s40265-023-01879-4. Epub 2023 May 18. Drugs. 2023. PMID: 37199856 Free PMC article.

2

Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.

Polak TB, van Rosmalen J, Uyl-de Groot CA. Polak TB, et al. Br J Clin Pharmacol. 2020 Sep;86(9):1819-1826. doi: 10.1111/bcp.14284. Epub 2020 Apr 7. Br J Clin Pharmacol. 2020. PMID: 32200551 Free PMC article.

3

Response to Open Peer Commentary "Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs".

Polak TB, van Rosmalen J, Uyl-De Groot CA. Polak TB, et al. Am J Bioeth. 2020 Nov;20(11):W4-W5. doi: 10.1080/15265161.2020.1820113. Am J Bioeth. 2020. PMID: 33103977 No abstract available.

4

Two decades of targeted therapies in acute myeloid leukemia.

Cucchi DGJ, Polak TB, Ossenkoppele GJ, Uyl-De Groot CA, Cloos J, Zweegman S, Janssen JJWM. Cucchi DGJ, et al. Leukemia. 2021 Mar;35(3):651-660. doi: 10.1038/s41375-021-01164-x. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589753 Review.

5

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals.

Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA. Polak TB, et al. BMJ Open. 2022 Jan 6;12(1):e052186. doi: 10.1136/bmjopen-2021-052186. BMJ Open. 2022. PMID: 34992108 Free PMC article. Review.

6

The DRUG Access Protocol: access inequality and European harmonisation.

Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA. Polak TB, et al. Lancet Oncol. 2022 May;23(5):e202. doi: 10.1016/S1470-2045(22)00098-5. Lancet Oncol. 2022. PMID: 35489346 No abstract available.

7

Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.

Polak TB, Cucchi DGJ, van Rosmalen J, Uyl-de Groot CA, Darrow JJ. Polak TB, et al. Front Pharmacol. 2022 May 23;13:913567. doi: 10.3389/fphar.2022.913567. eCollection 2022. Front Pharmacol. 2022. PMID: 35677436 Free PMC article.

8

A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer.

Li N, van Agthoven M, Willemse P, Uyl-de Groot C. Li N, et al. Anticancer Drugs. 2001 Jul;12(6):533-40. doi: 10.1097/00001813-200107000-00007. Anticancer Drugs. 2001. PMID: 11460000

9

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM. Jochems A, et al. Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629. Anticancer Drugs. 2018. PMID: 29659371

10

Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.

Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, Jager A, Uyl-de Groot CA. Franken MG, et al. Anticancer Drugs. 2018 Sep;29(8):791-801. doi: 10.1097/CAD.0000000000000648. Anticancer Drugs. 2018. PMID: 29846248

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

241 results

Search Page

Filters